Kura Oncology Inc
Gesloten
SectorGezondheidszorg
11.52 -4.64
Overzicht
Wijziging aandelenprijs
24u
Min
11.42
Max
12.03
Inkomsten | 5M -68M |
|---|---|
Verkoop | 2.6M 21M |
EPS | -0.77 |
Winstmarge | -327.331 |
Werknemers | 260 |
EBITDA | 7M -66M |
Volgende Winsten | 3 nov 2026 |
|---|
Marktkapitalisatie | 304M 1.2B |
|---|---|
Vorige openingsprijs | 16.16 |
Vorige sluitingsprijs | 11.52 |
Nieuwssentiment
By Acuity
19%
81%
26 / 339 Rangschikking in Healthcare
Kura Oncology Inc Grafiek
Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.
Gerelateerd nieuws
Peer Vergelijking
Prijswijziging
Kura Oncology Inc Prognose
Sentiment
By Acuity
26 / 339 Rangschikking in Gezondheidszorg
Nieuwssentiment
Zeer Sterk Bearish Bewijs
Volatiliteit
Onder gemiddelde
Nieuws Volume (RCV)
Boven gemiddelde
Financieel
Verkoop- en administratiekosten
Bedrijfskosten
Winst voor belastingen
Verkoop
Kosten van verkopen
Brutowinst op verkopen
Rente-uitgaven op schulden
EBITDA
Operationele winst
$
Over Kura Oncology Inc
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.